INTRODUCTION {#s1}
============

Wnt/β-catenin pathway is critical to multiple tumorigenesis \[[@R1]\]. Both genetic and epigenetic changes cause abnormal activation of Wnt pathway components that are involved in multiple cell functions, contributing to tumor initiation and development.

Wnt signaling is comprised of canonical Wnt/β-catenin and non-canonical Wnt signaling that are independent of β-catenin \[[@R2]\]. Increased expression of Wnt family members greatly increases the risk of breast tumor formation \[[@R3]--[@R5]\]. Moreover, a majority of breast cancer studies reveals that Wnt antagonists can be regulated by epigenetic changes. Importantly, DNA methylation is frequently detected in this pathway in multiple cancers, especially Wnt antagonists are frequently down-regulated by promoter CpG methylation, suggesting that aberrant epigenetic changes towards Wnt signaling, rather than gene deletion or mutation, are involved in breast tumorigenesis \[[@R2], [@R6]--[@R10]\].

*DKK2*, Like *DKK1, DKK3, DKK4* and *Soggy*, belong to the DKK family \[[@R11]\]. It locates at 4q25 and regulates Wnt/β-catenin signaling through binding to LDL receptor-related proteins (LRP5/6). *DKK1, 2* and *3*, but not *DKK4*, have typical CpG island in their promoters, thus are regulated by epigenetic mechanism via promoter CpG methylation \[[@R2]\]. *DKK2* has been shown to be downregulated or silenced by epigenetic mechanisms in several malignancies, including Ewing\'s sarcoma, kidney cancer, and ovarian cancer, same as *DKK3* \[[@R12]--[@R14]\]. Although *DKK2* is frequently silenced by promoter methylation, its effects on Wnt signaling in breast carcinogenesis are still unclear.

Here we investigated the expression and significance of *DKK2 in* mammary cancer, as well as its functions *in vivo* and *in vitro*. Our findings demonstrate that *DKK2* inhibited breast cancer growth through downregulating activated β-catenin levels. The tumor-specific promoter methylation of *DKK2* could be a potential marker for the early assessment of mammary cancer.

RESULTS {#s2}
=======

DKK2 is downregulated in breast carcinoma {#s2_1}
-----------------------------------------

*DKK2* downregulation in breast cell lines has been reported in our previous study \[[@R15]\]. Protein expression of DKK2 was examined in 30 paired primary tumors and appropriate surgical-margin tissues by immunohistochemistry (IHC). IPP6.0 analysis showed that DKK2 protein expression was significantly lower in breast tumors (0.201 ± 0.038) than that in surgical-margins (0.274 ± 0.049) (\*\*\**p* \< 0.001) (Figure [1A--1C](#F1){ref-type="fig"}). Furthermore, we showed that *DKK2* mRNA level was significantly lower in breast cancer tissues than that in paired surgical-margins by qRT-PCR (\**p* \< 0.05) (Figure [2C](#F2){ref-type="fig"}). Alternatively, the downregulation of *DKK2* was related to clinicopathological subtypes of breast cancer according to data from Oncomine database (Oncomine, Compendia Bioscience, Ann Arbor, MI) (Figure [2A, 2B](#F2){ref-type="fig"}) (*p* \< 0.00001). Altogether, these data indicated that the reduced *DKK2* expression was a solid fact in breast carcinoma.

![The expression levels of DKK2 in breast cancer tissues\
**(A)** The MOD of DKK2 protein in each case. **(B)** Representative images of DKK2 IHC staining in paired breast carcinomas and its surgical margin tissues. **(C)** Quantitative analysis of the MOD of *DKK2* expressions in two groups are shown as values of mean ± SD. \*\*\*, *p* \< 0.001(Student\'s *t*-test).](oncotarget-08-39443-g001){#F1}

![Expression and significant of *DKK2* in breast carcinoma\
**(A, B)** *DKK2* expression is reduced in breast carcinoma. Oncomine platform provides all data (<https://www.oncomine.org/>). BN: normal breast tissue; BA: breast adjacent tissue; BrCa: breast cancer tissue. **(C)** Expression of *DKK2* was detected by quantitative real-time PCR in human breast adjacent tissue and breast cancer tissues. **(D)** *DKK2* expression and prognostic analyses in breast carcinoma. Kaplan-Meier survival curves are presented to explicate prognostic significant of *DKK2*. Data from bc-GenExMiner. The *p* values shown was statistically significant.](oncotarget-08-39443-g002){#F2}

Prognostic analyses showed that higher levels of *DKK2* expression could herald a better survival rate \[hazard ratio (HR) = 0.74, *p* = 3.1 e-07\] (Figure [2D](#F2){ref-type="fig"}) \[[@R16]--[@R17]\]. These results indicated that *DKK2* downregulation may be a marker to evaluate the outcome of breast carcinoma.

Promoter CpG methylation downregulated *DKK2* expression {#s2_2}
--------------------------------------------------------

*DKK2* contains a typical CpG island \[[@R15]\]. To identify whether *DKK2* silencing was due to its promoter CpG methylation, we investigated methylation status of *DKK2*. *DKK2* was silenced in 7/8 breast cell lines (Figure [3A](#F3){ref-type="fig"}), while its CpG hypermethylation was detected in 7/9 cell lines (Figure [3A](#F3){ref-type="fig"}). To further determine whether *DKK2* silencing correlated with promoter methylation, we treated MDA-MB-231 and MCF7 cells with demethylation drug 5-Aza-dC or combined with TSA. Results showed that *DKK2* expression was remarkably restored after treatment, together with increased unmethylated alleles and decreased methylated alleles (Figure [3B](#F3){ref-type="fig"}). Thus, *DKK2* silencing or downregulation was the result of promoter CpG methylation in breast cancer cells.

![The methylation status of *DKK2* promoter in mammary carcinoma cell lines, primary tumor tissues and normal breast tissues\
**(A)** Promoter methylation of *DKK2 in* mammary carcinoma cells. "M" indicates methylated *DKK2*; "U" indicates unmethylated *DKK2*. **(B)** Restoration of *DKK2* expression by Aza with or TSA treatment in MDA-MB-231 and MCF7 cells. **(C)** Representative methylation of *DKK2* in mammary carcinoma and **(D)** normal tissues as measured by MSP.](oncotarget-08-39443-g003){#F3}

Furthermore, 98 primary breast carcinoma tissues and 21 normal mammary tissues were analyzed by MSP to investigate *DKK2* methylation in breast tumors. *DKK2* methylation was detected in 85/98 (86.7%) breast tumors, 4/21 (19%) in normal tissues, indicating that *DKK2* methylation was a common in breast cancer (Table [1](#T1){ref-type="table"}, Figure [3C, 3D](#F3){ref-type="fig"}). These results suggested that the promoter of *DKK2* is specifically methylated in breast tumors.

###### Methylation status of the *DKK2* promoter in primary breast tumors

  Samples        *DKK2* promoter   Frequency of methylation   
  -------------- ----------------- -------------------------- -------
  BrCa (n= 98)   83                13                         86.7%
  BNP (n=21)     4                 21                         19%

Note: BrCa, breast cancer; BNP, breast normal tissues

However, *DKK2* methylation was not statistically associated with age, tumor size, clinical stage, metastasis, or ER, PR, HER2 status of breast carcinoma patients through analyzing the *DKK2* promoter methylation and patient clinicopathological characters. All these results indicated that *DKK2* methylation is a potential marker for breast carcinoma early detection.

*DKK2* inhibits breast cancer cell growth and colony formation {#s2_3}
--------------------------------------------------------------

To explore the tumor suppressive function of *DKK2* in breast cancer, CCK8 assays and colony formation assays were performed in MDA-MB-231 and MCF7 cells. *DKK2* expression in *DKK2*-infected cells were verified via RT-PCR and western blot (Figure [4A](#F4){ref-type="fig"}). Compared to the control cells, there was a 40-65% reduction in colony formation in *DKK2*-expressed cells (\*\*\**p* \< 0.001, \*\**p* \< 0.01) (Figure [4B, 4C](#F4){ref-type="fig"}). Cell vitality, as determined by CCK8 assay, also remarkably declined at 24 h, 48 h, and 72 h (all \*\*\**p* \< 0.001) (Figure [4D](#F4){ref-type="fig"}).

![Inhibitory effect of *DKK2* in breast carcinoma\
**(A)** Expression of *DKK2* was confirmed by RT-PCR and western blot in vector- and *DKK2*- infected MDA-MB-231 and MCF-7 cells. **(B)** Representative images of CFA in vector- and *DKK2*-infected mammary carcinoma cells. **(C)** The histogram statistics of CFA. The mean ± S.E. data from three independent experiments (\*\*\**p* \< 0.001). **(C) (D)** Measurement of cell proliferation for vector- and *DKK2*- infected mammary carcinoma cells through CCK-8 assay. Three asterisks, *p* \< 0.001.](oncotarget-08-39443-g004){#F4}

*DKK2* delays cell cycle and induces apoptosis in mammary carcinoma cells {#s2_4}
-------------------------------------------------------------------------

Cell cycle analysis was performed to explore how *DKK2* affects cell proliferation. Compared to control cells, *DKK2* significantly increased the number of MDA-MB-231 and MCF7 cells in G0-G1 phase by 14% and 13%, respectively (\*\*\**p* \< 0.001) (Figure [5A](#F5){ref-type="fig"}). Acridine orange/ethidium bromide (AO/EB) double staining was performed to examine breast tumor cell apoptosis (Figure [5B](#F5){ref-type="fig"}). These data indicated that *DKK2* can inhibit cell growth by delaying the cell cycle in G0/G1 and inducing cell apoptosis. Western blot further showed increased expression of cleaved-PARP and caspases in *DKK*2 expressing cells (Figure [5C](#F5){ref-type="fig"}).

![Flow cytometric analysis\
**(A)** The cell cycle distribution in vector and *DKK2*- infected MDA-MB-231 and MCF7 cells detected by flow cytometry analyses. Representative images of cell cycle distribution (left) and statistical graphs of cell cycle changes (right) (\*\*\**p* \< 0.001). **(B)** AO/EB staining was used to examine cell apoptosis. The percentage of total apoptotic cells is calculated and indicated in histograms (\*\*\**p* \< 0.001). **(C)** DKK2 upregulated the expression levels of two classic markers of apoptosis, cleaved-PARP and cleaved-caspase 3, by western blot.](oncotarget-08-39443-g005){#F5}

DKK2 inhibits breast cancer xenografts\' growth in nude mice {#s2_5}
------------------------------------------------------------

Nude mice xenografts model was used to further assess the functions of DKK2 *in vivo*. No significant differences were observed in the various organs between the two group mice (data not shown). The average volume and weight of the tumors were significantly lower in DKK2 group than that in control group (\*\*\**p* \< 0.001) (Figure [6A, 6B](#F6){ref-type="fig"}). IHC and hematoxylin & eosin (H&E) staining were carried out to analyze DKK2 expression and tumor features of the xenografts nude mice, respectively. TUNEL analyses and Ki-67 staining were carried out to evaluate cell apoptosis and proliferation. Most tumor cells with frequently nuclear fragmentation were observed in xenografts with *DKK2*-expressing, along with downregulation of Ki-67 and increasing of apoptotic cells (Figure [6C, 6D](#F6){ref-type="fig"}). All these data indicated that DKK2 inhibits breast tumorigenesis.

![*DKK2* inhibited mammary carcinoma growth *in vivo*\
**(A)** Images of human breast tumor xenografts. **(B)** Comparative analyses of tumor growth curve for vector- and *DKK2-* infected MDA-MB-231 cells in nude mice xenografts (\*\*\**p* \< 0.001). **(C)** Representative photographs of H&E staining and IHC expression analyses of *DKK2*, Ki-67, and apoptosis as assessed by TUNEL assays in xenografts (400× magnification). **(D)** Comparative histogram of tumor weights in the two groups of nude mice (\*\*\**p* \< 0.001).](oncotarget-08-39443-g006){#F6}

*DKK2* suppresses migration and invasion via regulating epithelial- mesenchymal transition (EMT) in breast carcinoma {#s2_6}
--------------------------------------------------------------------------------------------------------------------

To further make clear the effects of DKK2 on cell migration, wound healing assays were performed. DKK2 stable cells migrated along the wound borderline slower than the control cells at 48 h, (all \*\*\**p* \< 0.001) (Figure [7A-7D](#F7){ref-type="fig"}) indicating that DKK2 could also inhibit cell migration in MDA-MB-231 and MCF7. Transwell® assays further identified that DKK2 expressing cells had a significantly decreased number of cells through the membrane. (\*\*\**p* \< 0.001) (Figure [7E, 7F](#F7){ref-type="fig"}).

![Ectopic expression of *DKK2* inhibited migration of breast cancer cells\
**(A, B, C, and D)** The cellular migration abilities (MDA-MB-231 and MCF7) were examined by wound healing assays. Photographs were captured at 0, 24, or 48 h. The ratio of wound healing was calculated (right). **(E, F)** *DKK2* inhibited the migration of tumor cells, 400×magnification (\*\*\**p* \< 0.001).](oncotarget-08-39443-g007){#F7}

To study underlying mechanisms of DKK2 on cell migration in breast cancer, cell morphological changes was firstly observed (Figure [8A](#F8){ref-type="fig"}). Cells expressing *DKK2* recovered cell adherence and contacts with each other, however, the control cells exhibited a scattering pattern, indicating that *DKK2* might be involved in tumor cell EMT. Western blot showed increased epithelial markers (E-cadherin and occludin), and decreased mesenchymal markers (N-cadherin and vimentin), in *DKK2* expressing cells (Figure [8B](#F8){ref-type="fig"}). Immunofluorescence staining further showed increased staining of E-cadherin and less staining of vimentin in the cytoplasm and the membranes of breast tumor cells expressing *DKK2* (Figure [8C](#F8){ref-type="fig"}). These results demonstrated that *DKK2* inhibits EMT in breast cancer cells.

![Ectopic expression of *DKK2* and the effects on EMT and Wnt signaling in breast tumor cells\
**(A)** Morphological changes of breast cells infected with control vector or *DKK2* by phase contrast microscopy. 400×magnification. **(B)** The thicker stress fibers of *DKK2* expressing cells and more fibers of the E-cadherin, but fewer and thinner fibers of the vimentin in *DKK2* expressing tumor cells. **(C)** Western blot analyses of EMT, and downstream target markers. **(D)** Representative stem cell markers were detected in *DKK2*-infected MDA-MB-231 and MCF7 cells by RT-PCR. \*Indicates significantly decreased band density. **(E)** Examination of β-catenin and its targets by western blot.](oncotarget-08-39443-g008){#F8}

As cell with stem cell properties is closely related to EMT for tumor cells, it is necessary to investigate whether *DKK2* could negatively regulate cell stemness in breast tumor cells. RT-PCR showed that *DKK2* caused the downregulation of most stem cell markers, including *OCT4*, *BMI1*, *SOX2*, *SOX3*, *MAD2*, *NANOG*, *ABCG2*, *STAT3*, and *RLF4 in MDA-MB-231 and MCF7* cells (Figure [8D](#F8){ref-type="fig"}). Again it indicated that DKK2 may inhibit both EMT and stemness of breast carcinoma cells.

DKK2 regulates the Wnt signaling pathway in breast tumor cells {#s2_7}
--------------------------------------------------------------

*DKK* family is an antagonist of Wnt pathway. Here we studied whether the tumor suppressive function of *DKK2* was related to its effects on this pathway. Our results showed that the restored expression of DKK2 in breast tumor cell lines significantly down-regulated active β-catenin. The downstream target genes of β-catenin, cyclin D1 and c-Myc were also confirmed to be downregulated (Figure [8E](#F8){ref-type="fig"}). Our findings indicated that *DKK2* inhibited β-catenin activity, thus inhibiting Wnt/β-catenin signaling in mammary cancer.

DKK2 inhibits angiogenesis *in vitro* and in conditioned medium {#s2_8}
---------------------------------------------------------------

Angiogenesis plays an important role in tumor growth. To understand whether attenuating new blood vessel formation contributes to tumor suppressive function of *DKK2*, Transwell^®^ assays for HUVECs in conditioned medium were performed to verify the effects of *DKK2* on the migration of HUVECs, when compared to control cells. HUVECs cell lines cultured in DKK2 conditional medium demonstrated a significantly decreased number of migrating cells compare with the empty vector group (\*\*\**p* \< 0.001) (Figure [9A, 9B](#F9){ref-type="fig"}).

![*DKK2* suppressed angiogenesis *in vitro*\
**(A, B)** Conditioned media from *DKK2*- infected breast tumor cells inhibited migration of HUVECs. Each experiment was performed three times. **(C, D)** Conditioned media from *DKK2*-expressing MCF7 cells suppressed HUVECs tube formation. **(E)** Primary antibodies targeting *DKK2* were used in conditioned media from *DKK2*-expressing cells. Effects of *DKK2*-expressing MCF7 cells on HUVECs tube formation were measured (\*\*\**p* \< 0.001).](oncotarget-08-39443-g009){#F9}

Tube formation assays were further performed *in vitro*. As shown, *DKK2* significantly disrupted microtube formation of HUVECs on Matrigel^®^ (\*\*\**p* \< 0.001) (Figure [9C, 9D](#F9){ref-type="fig"}). After incubation with DKK2 primary antibodies in conditioned media, DKK2 antibody could partly reverse microtubule formation of HUVECs (\*\*\**p* \< 0.001) (Figure [9E](#F9){ref-type="fig"}).

DISCUSSION {#s3}
==========

At present, a large amount of studies reported that Wnt signaling was important in initiation and development of breast carcinoma. Several Wnt/β-catenin antagonists were epigenetically repressed in breast cancer \[[@R1]\], including *WIF1* \[[@R18]\], *SFRP1* \[[@R19]\], *SFRP2* \[[@R20]\], *SFRP5* \[[@R21]\], *DKK1* \[[@R22]\], and *DKK3* \[[@R15]\]. Within the *DKK* family, the *DKK2* gene is a critical gene involved in the inhibition of Wnt signaling. Recently, silencing of *DKK2* was reported to be a valuable biomarker for multiple malignancies \[[@R12]--[@R14]\], but its roles in breast cancer are still unclear. Thus, defining the underlying mechanisms of *DKK2* in breast cancer development may support the idea that DKK2 may be a potential treatment target and marker in breast carcinoma. Here, *DKK2* promoter methylation was detected in 77.8% (7/9) of breast cell lines and in 86.7% of breast tumor samples. No methylation was observed in SK-BR-3 and T47D cells with *DKK2* downregulation, which might be caused by the heterogeneity of tumor cells, and suggests that other mechanisms such as histone deacetylation might be also involved. Our data showed that the methylation status and expression of *DKK2* were not correlated with the clinical features of breast tumor, such as pathological grade, ER status, and lymph node metastasis level. However, *DKK2* can be a new biomarker for early assessment of breast tumor.

Our results also showed that ectopic expression of *DKK2* can induce apoptosis, suppress cell growth, and halt cell cycle in G0/G1 in breast tumor cell lines, in agreement with previous reports \[[@R12]--[@R14]\]. *DKK2* also suppressed cell migration by interfering with EMT. Moreover, we showed that *DKK2* suppressed β-catenin activation and expression of its downstream genes. Numerous studies have demonstrated WNT pathway plays diverse roles in regulating the vascular system \[[@R23]--[@R25]\]. Indeed, both Wnt1 and Wnt5a have been shown to regulate two critical processes for angiogenesis, endothelial cell (EC) proliferation and migration \[[@R26]\]. Actually, the anti-angiogenic activities of other Wnt pathway antagonists also were reported in some studies, including sFRPs, WIF1, DKK1 and DKK4 \[[@R27]--[@R29]\]. On the other hand, it is interesting that in some cases Wnts seem to be inhibitory of angiogenesis, WNT1 and WNT5 were found to inhibit proliferation of endothelial cells \[[@R30]\]. Previous studies showed that *DKK2* boosts angiogenesis and tissue recovery by regulating the activation of Cdc42 in rodent and EC cells \[[@R31]\]. Our results demonstrated that *DKK2* dramatically suppresses angiogenesis compared with controls in cultured human endothelial cells. After incubating with DKK2 primary antibodies in conditioned media, DKK2 antibody could partly reverse microtubule formation of HUVECs. Previous studies have demonstrated double roles for the WNT signaling in angiogenesis. One possible explanation for this might be that DKK2 may inhibit or induce angiogenesis through directly affect WNT signaling in breast cancer, depending on different Wnt signaling acitivity in different microenvironment. Another possible explanation is that DKK2 could regulate angiogenesis through other pathways such as Notch/Dll4 and VEGF. DKK2 also influence pro-angiogenic factors to regulate angiogenesis. This remains an unmet need for an in-depth study to identify the mechanism of *DKK2*.

MATERIALS AND METHODS {#s4}
=====================

Cell lines and tumor samples {#s4_1}
----------------------------

Several breast tumor cell lines (BT549, MDA-MB-231, MDAMB-468, MCF-7, T47D, SK-BR-3, YCC-B1, YCC-B3, and ZR-75-1) were used. These cell lines were obtained from the ATCC (American Type Culture Collection, Manassas, VA, USA) or collaborators. All cell lines were maintained in RPMI 1640 media (Gibco-BRL, Karlsruhe, Germany) supplemented with 10% fetal bovine serum (FBS; PAA Laboratories, Linz, Austria), 100 U/mL penicillin, and 100 mg/mL streptomycin at 37°C in a humidified atmosphere containing 5% CO~2~ \[[@R32]--[@R33]\]. All tissues were obtained from patients who underwent primary surgery at the Department of Endocrine and Breast Surgery, The First Affiliated Hospital of Chongqing Medical University \[[@R34]--[@R35]\]. Clinical and pathological data of all the participants were obtained, and their demographics are summarized in Table [2](#T2){ref-type="table"}. This research was approved by the Institutional Ethics Committees of the First Affiliated Hospital of Chongqing Medical University (\#20130306), and conformed to the tenets of the Declaration of Helsinki.

###### Clinicopathologic features of *DKK2* methylation in breast cancer

  Clinicopathological features   Number (n=98)   *DKK2* promoter methylated status   *p* value   
  ------------------------------ --------------- ----------------------------------- ----------- -----------
  **Age**                                                                                        0.171
   ≤40                           9               6                                   3           
   \>40                          74              66                                  8           
   unknown                       15              13                                  2           
  **grade**                                                                                      0.731
   I                             6               6                                   0           
   II                            48              42                                  6           
   III                           5               4                                   1           
   unknown                       39              33                                  6           
  **Tumour size**                                                                                0.975
   \<2.0 cm                      15              13                                  2           
   ≥2.0 cm ≤5.0cm                63              55                                  8           
   \>5.0cm                       5               4                                   1           
   unknown                       15              13                                  2           
  **Lymph node metastasis**                                                                      0.494
   Positive                      39              32                                  7           
   Negative                      44              40                                  4           
   unknown                       15              13                                  2           
  **ER status**                                                                                  0.782
   Positive                      36              32                                  4           
   Negative                      23              19                                  4           
   unknown                       39              34                                  5           
  **PR status**                                                                                  **0.523**
   Positive                      29              26                                  3           
   Negative                      30              25                                  5           
   unknown                       39              34                                  5           
  **HR status**                                                                                  0.313
   \>+++                         46              39                                  7           
   ++                            10              9                                   1           
   \<+                           42              37                                  5           

DNA and RNA extractions {#s4_2}
-----------------------

Genomic DNA was isolated from cell lines and tissues using DNAzol^®^ reagent (Invitrogen, Rockville, MD, USA) and the QIAamp^®^ DNA Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer\'s protocols. Total RNA was extracted from cell lines and tissues using TRI Reagent® (Molecular Research Center, Cincinnati, OH, USA) \[[@R32]\]. Total DNA and RNA were detected by gel electrophoresis. Samples were stored at −80°C until use.

5-aza-deoxycytidine and trichostatin A treatments {#s4_3}
-------------------------------------------------

5-aza-2′-deoxycytidine (5-aza-dC), a DNA methyltransferase (DNMT) inhibitor, makes DNMT inactivation through DNMT covalent bonding with thiol on cysteine residues, resulting in reactivation genes silenced by promoter methylation. Trichostatin A (TSA), a histone deacetylase inhibitor, plays a significant role in controlling the tightness of DNA around histone. Combination treatment of TSA and 5-Aza-dC results in the synergistic activation of methylated genes.

As previously described \[[@R32]\], breast cancer cell lines were treated with 10 mmol/L 5-aza-2-deoxycytidine (Aza) (Sigma-Aldrich, Steinheim, Germany) for 3 days and further treated with or without 100 nmol/L TSA (Sigma-Aldrich) for an additional 24 h.

Reverse transcriptase-PCR and real-time PCR {#s4_4}
-------------------------------------------

The reverse transcriptase-polymerase chain reaction (RT-PCR) was performed as previously described \[[@R32], [@R36]\]. *GAPDH* was amplified as a control. Samples were assayed in a 10 μL reaction mixture containing 2 μL of cDNA. The primer sequences are in listed in Table [3](#T3){ref-type="table"}. RT-PCR was carried out using Go-Taq (Promega, Madison, WI, USA). Reaction was under the following conditions: 32 cycles for *DKK2* and 23 cycles for *GAPDH*. Real-time PCR was performed according to the manual (HT7500 System; Applied Biosystems), the expression level of *DKK2* in paired surgical margin tissues was considered as baseline.

###### List of primers used in this study

  PCR      Primer    Sequence (5′-3′)            Product size (bp)   PCR Cycles   Annealing temperature (°C)
  -------- --------- --------------------------- ------------------- ------------ ----------------------------
  MSP      DKK2-M1   AGAGTTAAATCGTCGAGATTTC      146                 40           60
           DKK2-M2   CTAAAAACAATCAAATACGAAACG                                     
           DKK2-U1   GGAGAGTTAAATTGTTGAGATTTT    149                 40           58
           DKK2-U2   ACTAAAAACAATCAAATACAAAACA                                    
  RT-PCR   DKK2-F    GTACCAAGGACTGGCATTCG        169                 32           55
           DKK2-R    ATCTCGGTGGCAGCGCTTCT                                         

Bisulfite treatment and methylation-specific PCR (MSP) {#s4_5}
------------------------------------------------------

Bisulfite modification of DNA and methylation-specific PCR (MSP) were carried out as previously described \[[@R37]--[@R38]\]. The methylation-specific primers are listed in Table [2](#T2){ref-type="table"}. MSP analysis revealed no amplified product in any not-bisulfited DNA by MSP primers, thus specific. MSP was performed for 40 cycles using AmpliTaq^®^-Gold DNA Polymerase (Applied Biosystems) with annealing temperatures of 60°C or 58°C. Methylated and non-methylated human DNAs were used as positive and negative controls, respectively. MSP products were identified on 2% agarose gel containing 100 bp DNA markers (MBI Fermentas, Vilnius, Lithuania).

Construction of LV-*DKK2* and stable cell lines {#s4_6}
-----------------------------------------------

To construct human *DKK2* lentiviral over-expression vector (LV-*DKK2*), using normal testis cDNA as a template, the *DKK2* fragment was amplified by PCR to construct pEZ-Lv105 shuttle plasmid by directly clone. Shuttle plasmid along with and helper plasmids mixture were co-transfected into 293T cells to package LV-*DKK2*, and the virus titer was determined by real-time PCR and drug screening method, respectively. MDA-MB-231 and MCF7 stable cells infected with LV-*DKK2* were obtained under the pressure of puromycin (2 μg/ml, BioVision, Inc., CA, USA). Total RNA from infected cells was extracted, treated with TURBO™ DNase (Ambion, Austin, TX, USA). Proteins from two cell lines were solubilized and extracted using the Protein Extraction kit (Thermo Scientific, \#23225). RT-PCR and western blot were used to measure ectopic expression of *DKK2* prior to the other experiments.

Colony formation assays {#s4_7}
-----------------------

Colony formation assays were performed as previously described \[[@R32]\]. Cells infected by lentivirus were plated in 6-well plates at a density of 1 × 10^3^ cells/well. Surviving colonies (≥ 50 cells/colony) were counted after staining with Gentian violet. All experiments were performed in triplicate.

Cell proliferation assay {#s4_8}
------------------------

MDA-MB-231 and MCF7 stably cells were cultured in 6-well plates and grown overnight. After 24, 48, and 72 h, proliferation was measured using the Cell Counting Kit-8 (CCK-8; Beyotime, Shanghai, China) \[[@R32]\]. The experiments were independently repeated three times.

Analyses of the cell cycle and apoptosis {#s4_9}
----------------------------------------

To assess cell cycle status \[[@R39]\], MDA-MB-231 and MCF7 cells were seeded (1 × 10^6^ cells/well) in 6-well plates. After 48 h, cells were collected and centrifuged at 800 rpm for 5 min, then washed with phosphate-buffered saline (PBS) twice, and fixed in ice-cold 70% ethanol for at least 24 h, and treated with 100 μL of 50 mg/L propidium iodide for 30 min at 4°C in the dark. The cell cycle data were analyzed by CELL Quest software (BD Biosciences, San Jose, CA, USA). For apoptosis analyses, acridine orange/ethidium bromide (AO/EB) fluorescence staining was used \[[@R39]\]. Cells were re-plated in 6-well plates. After 24 h, cells were washed in PBS three times then stained with AO/EB for 5 min and visualized immediately under a fluorescence microscope (LEICA CTR4000B; Leica Microsystems, Buffalo Grove, IL, USA). The percentage of apoptotic cells was then calculated by the formula: percentage of apoptotic cell (%) = (amount of apoptotic cells/total cells examined) × 100%.

Wound healing and Transwell^®^ assays for cell migration {#s4_10}
--------------------------------------------------------

Cell mobility was assessed using a scratch wound healing assay. *DKK2* stably infected cells (MDA-MB-231 and MCF7) were cultured in 6-well plates until confluent. The cell layers were carefully wounded using sterile tips and then cells were washed with PBS, cultured in 5% FBS-RPMI 1640. After incubation for 12, 24, and 48 h, the cells were photographed under a 10× objective lens. Experiments were performed in triplicate. *In vitro* Transwell® assays were carried out as described previously \[[@R40]\].

Microtube formation and conditioned medium assays {#s4_11}
-------------------------------------------------

Conditioned media were collected by incubating MCF7 breast cancer cells infected with lentivirus LV-DKK2 or vector alone without serum for 24 h. After Matrigel® culturing, (Corning Life Sciences, Bedford, MA, USA) cells were thawed on ice (approximately 1-2 h). The Matrigel® was added into the 96-well plates (50 μL into each well) that were then incubated at 37°C for 30 min to allow the Matrigel® to polymerize. A total of 1 × 10^4^ human umbilical vein endothelial cells (HUVEC) were seeded into each well and incubated with 100 μL conditioned media from LV-DKK2 or vector alone stably infected breast cancer cells (MCF7). HUVECs were then incubated for 6 h to allow microtubule formation. Image analyses of tube lengths were carried out using Image J software. To eliminate other factors effecting microtubule formation, anti-DKK2 primary antibody was added in the conditioned media. Transwell® assays for HUVECs in condition medium were performed to further determine whether *DKK2* influenced the migration of HUVECs.

The co-culture system was used to detect the influence of DKK2 on HUVEC migration. Briefly, HUVEC cells were seeded at a density of 2 × 10^5^ cells/mL into the upper chamber of a Transwell® (Corning Life Sciences) with inserts containing 8-μm pore size polyethylene terephthalate (PET) membranes (Corning Life Sciences). MDA-MB-231 or MCF7 with LV-*DKK2* or vector was seeded in the lower chamber with RPMI 1640 containing 10% FBS. After a 24h incubation at 37°C, cells remaining in the upper chamber were removed carefully with a cotton swab and the membrane was cut with an operating knife. The side facing the lower chamber was stained with 0.05% crystal violet and attached cells were counted under a light microscope. Each experiment was performed three times.

Indirect immunofluorescence determinations {#s4_12}
------------------------------------------

MDA-MB-231 and MCF7 cells were seeded (1×10^6^cells/well) in 24-well plates on coverslips and allowed to grow overnight, the cultures were then infected transiently with LV-*DKK2*. Coverslips were stained by indirect immunofluorescence double staining as described previously \[[@R40]\]. Briefly, cells were incubated with primary antibodies against E-cadherin (\#1702-1; Epitomics), vimentin (\#2707-1; Epitomics), or DKK2 (ab38594; Abcam), and then incubated with Alexa Fluor® 594- (Invitrogen) or FITC-conjugated (Dako, Carpinteria, CA, USA) secondary antibody against mouse or rabbit IgG. Cells were then counterstained with 4′, 6-diamidino-2-phenylindole (DAPI) and imaged with a confocal laser scanning microscope.

Tissue microarray and immunohistochemistry analyses {#s4_13}
---------------------------------------------------

To evaluate the expression levels of DKK2 in breast cancer tissues, tissue microarrays (TMA) were constructed using paraffin embedding, including 30 pairs of primary tumors and corresponding tumor margin tissues (Biochip Co., Ltd., Shanghai, China). IHC was performed according to IHC procedure as described previously \[[@R32], [@R41]\]. Anti-DKK2 was obtained from abcam (ab38594; Abcam). Sections were incubated with primary antibody (1:200 dilution) overnight at 4°C, followed by the secondary antibody (1:2000 dilution) at 37°C for 30 min. Finally, the slides were counterstained with hematoxylin. The mean optical density (MOD) was analyzed using IPP6.0 (Image Pro Plus 6.0, Silver Spring, MD, USA)

*In vivo* tumor model {#s4_14}
---------------------

Animal experiments were performed to determine whether *DKK2* inhibits tumor growth *in vivo*. Female BALB/c nude mice (aged 4-6 weeks, weighing 18-22 g) were purchased from the Experimental Animal Center of Chongqing Medical University (CQMU), China. This study was approved by ethics committee of CQMU. Stable *DKK2*-expressing MDA-MB-231 cells or control cells (3 × 10^6^ cells in 0.1 mL PBS) were injected into the backs of female nude mice (n=6). Tumor diameter was measured every 3 days for 30 days. Tumor volume (mm^3^) = length × width^2^ × 0.52.

Terminal deoxynucleotidyl transferase (TUNEL) analyses {#s4_15}
------------------------------------------------------

TUNEL assay was used to detect apoptotic cells in tumor xenograft tissues following our previously described procedures \[[@R41]\]. TUNEL apoptosis detection kit was provided by Roche (Roche Applied Science, Pleasanton, CA, USA). Images were captured by Leica LSM 400 laser scanning microscope (Leica), and the rate of apoptosis was quantified using Image Pro Plus software (Media Cybernetics).

Western blot {#s4_16}
------------

Western blot was performed as described previously \[[@R34]\]. A total of 40μg of protein lysates were separated by sodium dodecyl sulphate/polyacrylamide gel electrophoresis (SDS-PAGE) and then transferred onto a polyvinylidene difluoride (PVDF) membrane (Bio-Rad, Hercules, CA, USA). The primary antibodies were against: DKK2 (ab38594, Abcam), active β-catenin (\#05-665; Merck Millipore, Billerica, MD, USA), total β-catenin (\#2677; Cell Signaling Technology, Danvers, MA, USA), c-Myc (\#1472-1; Epitomics, Cambridge, MA, USA), cyclin D1 (\#1677-1; Epitomics), occludin (ab31721; Abcam), vimentin (\#2707-1; Epitomics), Ecad (\#1702-1; Epitomics), N-cadherin (ab98952;Abcam), and β-actin (LK-ab008-100; Liankebio, China), and GAPDH (\#AE082046; Beijing Biosynthesis Biotechnology, Beijing, China) was used as a control. Proteins were visualized using an enhanced chemiluminescence kit (Amersham Pharmacia Biotech, Piscataway, NJ, USA).

Statistical analyses {#s4_17}
--------------------

Statistical analyses were performed with SPSS software, version16 (SPSS, Chicago, IL, USA). Student\'s *t*-test, the x^2^ test, and Fisher\'s exact test were used to compare methylation status and clinicopathological parameters \[[@R39]\]. For all tests, *p* \< 0.05 was considered statistically significant.

CONCLUSION {#s5}
==========

All in all, our data demonstrated that *DKK2* can inhibit breast carcinoma growth via suppressing Wnt/β-catenin signaling. Furthermore, the *DKK2* promoter methylation status could be a potential tumor marker for early found of mammary carcinoma, or even offer a new therapeutic method for breast carcinoma.
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DKK2

:   Dickkopf-related protein 2

LRP

:   LDL receptor-related proteins

MSP

:   methylation-specific PCR

AO/EB

:   acridine orange/ethidium bromide

HUVECs

:   human umbilical vein endothelial cells

EC

:   endothelial cells

TUNEL

:   Terminal deoxynucleotidyl transferase

Aza

:   5-aza-2′-deoxycytidine

TSA

:   Trichostatin A

EMT

:   epithelial-mesenchymal transition
